The Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed) from the National Institutes of Health (NIH) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources, new methods, and approaches that can be applied in testing strategies to help understand the role of environmental chemicals in the etiology of the neurodevelopmental disorders. There is a need for novel and innovative approaches including New Approach Methodologies (NAMs) that can provide effective ways to address current challenges and gaps in the assessment of Developmental Neurotoxicity (DNT). These screening systems or technologies, when fully developed and validated with appropriate throughput and controls, are expected to provide cost-effective, quicker and/or comprehensive results to understand the underlying role of environmental chemicals in the DNT. Applications are open to researchers at research institutions in the USA. The grant provides funding of up to 2 million USD for up to 5 years.
Funding opportunity number: RFA-ES-23-008.
Letters of intent are due on June 7, 2023.
Applications close on: July 7, 2023.
Menu
